Carter Peggy L
University of Michigan College of Pharmacy, Ann Arbor, 48106-1065, USA.
Postgrad Med. 2002 Sep;112(3 Suppl):18-25. doi: 10.3810/pgm.09.2002.suppl19.101.
Respiratory tract infections are a major health problem worldwide. Streptococcus pneumoniae remains the most prevalent respiratory tract pathogen. Because of the increasing prevalence of antibiotic resistance in S pneumoniae and other respiratory tract pathogens, development of new antibacterials has become necessary to treat infections that no longer respond to commonly used agents. Telithromycin, a ketolide, is a potent new oral agent designed to treat community-acquired respiratory tract infections and is especially effective against S pneumoniae strains that are resistant to penicillins and macrolides.
呼吸道感染是全球主要的健康问题。肺炎链球菌仍然是最常见的呼吸道病原体。由于肺炎链球菌和其他呼吸道病原体的抗生素耐药性日益普遍，开发新的抗菌药物对于治疗不再对常用药物有反应的感染变得必要。泰利霉素是一种酮内酯类药物，是一种强效的新型口服制剂，旨在治疗社区获得性呼吸道感染，对耐青霉素和大环内酯类的肺炎链球菌菌株特别有效。
